Ovarian Cancer Clinical Roundup
(QMUL [UK]) Aug 23, 2020 - A new two-stage surgical approach for cancer prevention is highly acceptable among premenopausal women at high risk of ovarian cancer, according to research led by Queen Mary University of London.
(Yahoo! Finance) Aug 21, 2020 - Myriad Genetics, Inc. announced today that the American Society of Clinical Oncology (ASCO) has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.
(Journal Of Clinical Pathways) Aug 18, 2020 - Working age patients with metastatic ovarian cancer experience significantly higher costs compared to those without cancer, according to findings from an analysis published in the Journal of Managed Care & Specialty Pharmacy (2020;26:962-970. doi:10.18553/jmcp.2020.26.8.962).
(USC News) Aug 16, 2020 - The tool, developed by USC researchers, could help identify patients with the most to gain from a clinical trial as well as guide therapeutic targets.
(J Clin Oncol) - 2020-08-21
(Cancer Res) - 2020-08-19
(Clin Cancer Res) - 2020-08-14
(J Clin Oncol) - 2020-08-13
At the ASCO20 Virtual Education Program, presenter Kathleen Moore, MD, Professor of Gynecologic Oncology, University of Oklahoma Health Sciences Center, summarized data from three groundbreaking trials of newly-approved PARP inhibitors in advanced ovarian cancer to make sense of the new treatment paradigm.
Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, and Dr. Morrissey, Obstetrics and Gynecology and Women's Health Institute, Cleveland Clinic Weston, discuss high-grade serous ovarian cancer recurrence regarding surgery vs. chemotherapy